DNA Script’s €46 Million Extension of Series B Financing


Dechert advised DNA Script on the deal.

DNA Script, the global leader in enzymatic DNA synthesis, completed the extension of its Series B financing for nearly €46 million, bringing the total amount of the transaction to approximately €80 million.

Existing investors Illumina Ventures, Merck Ventures, Life Sciences Partners (LSP), Bpifrance Large Venture and Danaher LifeSciences are participating in this fundraising round, alongside new investors Casdin Capital, Agilent Technologies andAlexandria Real Estate.

The financing will allow DNA Script to strengthen its workforce to accelerate research and development of new products andto prepare for the product launch of its DNA sequencing printer on the American and European markets.

The Dechert team advising DNA Script included partner Anne-Charlotte Rivière (Picture) and associate Claire Tanguy.

Involved fees earner: Anne-Charlotte Rivière – Dechert; Claire Tanguy – Dechert;

Law Firms: Dechert;

Clients: DNA Script SAS;